chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Two weeks after getting the vaccine joint pain began in my right middle finger and swelling. At the same time I began to experience heavy hair loss. My Dr attributed it to the vaccine. I received an MRI which showed a lot of fluid around the finger. He rx'd me Meloxicam. The joint pain resolved itself after about 3 months.
Lymph node swelling on left side of neck, about a ping pong ball sized with a smaller node next to it.  This has continued up to this day (day 12)  On day 10, large red circle around the vaccine area, about 2.5 inches in diameter and has continued to this day
SWELLING AT INJECTION SITE, SEEN SCHOOL NURSE ON 04/21/2008, APPLIED ICE TO AREA.
Patient and sister are identical twins. Patient did not experience symptoms as severe as sister, but her school sent her home today with a fever of 101 degrees.
continuous cough, high fever 105 and over for 5 days, unable to perform daily activities or attend school, muscle weakness, and severe headache. unable to eat, nausea, shortness of breath. dehydration.  treatment consisted of Doctor visits with augmentin and Zithromax prescriptions and inhaler.  Symptoms progressed and required ER visit on 11/28/18. was provided with IV fluids for dehydration. Decadron steroids and breathing treatments for one week.
This spontaneous report as received from a medical assistant refers to unspecified number of patients of unknown age and gender. The patients' medical history, current conditions and concomitant medications were not reported. On an unknown date, the patients were vaccinated with improperly stored doses of GARDASIL 9 lot # L024993 and expiry date: 17-OCT-2017 (route and dose were not reported). Other suspect therapies included PEDVAXHIB (route and dose were not reported), lot # M001813 and expiry date: 14-OCT-2018 and ROTATEQ, lot # L042215 expiry date: 02-AUG-2017 (route and dose were not reported). The vaccine was exposed to a temperature frame of -0.5 degrees Centigrade for a duration of 5 hours 38 minutes. There were no previous excursions. The call was because of a data logger. No adverse effects were reported. There was no product quality complaint involved. This is one of the several reports from the same reporter. Additional information has been requested.
This spontaneous report was received from a physician refers to a patient of unknown age and gender. On an unknown date in 2010, the patient was vaccinated with dose 1, GARDASIL (lot#, expiration date and route not reported). Patient sought medical attention on 24-OCT-2013 for "another problem" which began on an unspecified date approximately in 2013. On 24-OCT-2013 the patient was vaccinated with dose 2 GARDASIL (lot#, expiration date and route not reported). The outcome of the reported event was unknown. Physician additionally stated that the "problem" was not related to GARDASIL. Additional information has been requested.
Diaraeha, chills, fatigue, & soreness. Flu like symptoms.
Client recieved four vaccines on 4/2/09. The client parent requested all vaccine be given in the same extremity due to a previous injury in the other arm and the client fear of being unable to walk if we used the lower extremities. The parent reports that the Right arm was swollen and became very red and sore on 4/4/09. The client also had reported a headache which began on that date and a low grade fever. Her mother treated her with Motrin. On 4/6/09 the mother called to report that the client began vomiting the night before and that her arm was still swollen but not warm to touch and appered to be improving. The mother was advised to take her daughter to her doctor to be evaluated. The client's mother was contacted on 4/8/09 and informed that the client had been admitted to Hospital. On 4/13 futher follow up revealed that the client was home and has been diagnosed with parietal epliepsy.  4/16/09 MR received for DOS 4/8-10/2009 with D/C DX:  Morbid Obesity.  Pseudotumor Cerebri.  Abnormal EEG. Pt initially presented to PCP with c/o dizziness upon standing, one episode of nausea and vomiting,  and worsening of chronic H/A (~9 month hx). Pt recently fell out of a chair but did not have LOC. Pt sent to local hospital and transferred to current facility for neuro w/u. Started on Topamax after abnormal EEG. Pt still reporting mild dizziness and H/A at d/c.
warmth at injection site; I slept longer then normally I do; soreness; Received 3rd dose being not immunocompromised; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 27-Sep-2021 and was forwarded to Moderna on 27-Sep-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (warmth at injection site), HYPERSOMNIA (I slept longer then normally I do), OFF LABEL USE (Received 3rd dose being not immunocompromised) and MYALGIA (soreness) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 034C21A, 013M20A and 23M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 25-Sep-2021, the patient experienced OFF LABEL USE (Received 3rd dose being not immunocompromised). On an unknown date, the patient experienced VACCINATION SITE WARMTH (warmth at injection site), HYPERSOMNIA (I slept longer then normally I do) and MYALGIA (soreness). On 25-Sep-2021, OFF LABEL USE (Received 3rd dose being not immunocompromised) had resolved. At the time of the report, VACCINATION SITE WARMTH (warmth at injection site), HYPERSOMNIA (I slept longer then normally I do) and MYALGIA (soreness) outcome was unknown.            No concomitant medications were reported.  No treatment medications were reported.  Patient reported that she was not immunocompromised however she was given third shot. Patient does not recall the site of administration for doses 1 and 2.   This case was linked to MOD-2021-333240, MOD-2021-333346 (Patient Link).; Sender's Comments: This case concerns a  70-year-old, male patient with no relevant medical history, who received the third dose of Moderna COVID-19 Vaccine, however, the patient was not immunocompromised, therefore, it is considered to be Off label use. The patient experienced the unexpected events of vaccination site warmth and hypersomnia, as well as the expected event of myalgia. The events occurred after the third dose of Moderna COVD-19 Vaccine, however, the temporal relationship was unknown as the start date of the events was not provided. The rechallenge was not applicable, since the patient received the third dose of the vaccine and no additional doses will be given. The company causality for Off label use is not applicable. The benefit-risk relationship of Moderna COVID-19 Vaccine is not affected by this report.
Left shoulder pain starting approx. 8 hrs after vaccination. Pain continued after 1 week, sought the advice of Dr. from Occupational Health @ Hospital. He stated it was bursitis from injection. He recommended ibuprofen 600mg three times a day and if not better in 1 week return to OHS for full evaluation and probable physical therapy.
Information has been received from a physician concerning a 2 month old patient who was vaccinated with a dose of Rotateq and began crying inconsolable for 4-5 hours after the dose was given. The patient recovered. Unspecified medical attention was sought. Additional information has been requested. Follow-up information from the physician indicated that the patient had persistent screaming until 6 pm. The exam was normal and the patient recovered the same day, on 05-FEB-2007.
This is a spontaneous report from a contactable consumer. A patient of unspecified age and gender received PREVNAR 13, via an unspecified route of administration at single dose on an unspecified date for immunisation. The patient medical history and concomitant medications were not reported. The patient developed a rash on both arms within 2 weeks of being vaccinated on an unspecified date with outcome of unknown. No follow-up attempts are possible, information about batch/lot number cannot be obtained.
Auto-inoculation of vaccinia virus to left groin region. Treated with local wound care and discharged from ward. no further complications.
received on 2-8-2022, received another on 6-17-2022; This case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 13-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number MR5RK, expiry date 21st September 2023) for prophylaxis.   Previously administered products included Boostrix (1st dose received on 8th February 2022 in left arm).   On 17th June 2022, the patient received Boostrix (intramuscular) .5 mg/ml. On 17th June 2022, unknown after receiving Boostrix, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered was unknown.   Additional Information: GSK Receipt Date: 17-Jun-2022 Reporter's comments: This case was reported by the healthcare professional office for Boostrix administration error. The patient received a Boostrix on 8th February 2022 by their office. The same patient received another Boostrix vaccine on 17th June 2022 in the left arm at the same office. The consent to follow up was given. Additional Supportive Information: The patient received extra dose of Boostrix in error, which led to extra dose administered.
The client requested Moderna booster bivalent, given Moderna monovalent booster by mistake. No signs or symptoms of a reaction. The client was called by health department staff and was informed of the error. Appointment made for revaccination with bivalent Moderna booster for November 15th. This is in 2 months which is indicated by CDC for revaccination.
1/7/21: MODERATE BODY ACHES AND MILD JOINT PAIN. 1/8/21 MORNING: SEVERE BODY ACHE, CHILLS, JOINT PAIN, LOW GRADE FEVER (99.8) AND SEVERE HEADACHE. SWOLLEN FACE AND ARM PAIN. 1/8 NIGHT: HIGH GRADE FEVER (101.4). 1/10: HIGH GRADE FEVER (101.3 REACHING HIGHEST OF 102.9). SEVERE BODY ACHES, CLUSTER HEADACHE/MIGRAINE, JOINT PAIN. CILLS, COLD SEATS, LOSS OF APPETITIE, NAUSEA. SWOLLEN FACE AND ARM PAIN. 1/11 MORNING: LOW GRADE FEVER, MODERATE BODY ACHES, CHILLS AND COLD SWEATS, NAUSEA (STRONGER), LOSS OF APPETITE AND STOMACH ACHE, DIARRHEA, AND ARM PAIN. 1/11 AFTERNOON AND NIGHT: MODERATE STOMACH ACHE, NAUSEA. 1/12: STILL MILD NAUSEA AND LOSS OF APPETITE, ARM PAIN. TOOK IBUPROFEN, TYLENOL.
On Wednesday, March 10, 2021,I started having muscle pain throughout my left and right legs.  Things and calves were like walking on raw nerve ends.  I had all types of tests, x-rays, MRI?s and dr. visits to try to find the cause.  This pain continued through March 31, until  I was finally given a prescription for a steroid by my internist who believed this pain was being caused by the Johnson & Johnson covid 19 vaccination because of the time frame between the vaccine I was given and when the symptoms began.  The pain while on steroids has disappeared.  I am, as of this date, on the third day of a seven day course of the steroid medication.  The pain subsided on day two of the medication.
Information was received from a 83 year old male with cholesterol and a history of valve replacement and transient ischemia attack x 3 who on 06-SEP-2012 was vaccinated with ZOSTAVAX. Concomitant medications included lovastatin and PLAVIX. The patient stated he was told by nurse in the health care physician's office that he would be vaccinated with ZOSTAVAX and the flu vaccine when he came in. The patient reported on 06-SEP-2012, he was given one injection and billed for ZOSTAVAX and flu vaccine (unspecified). The patient reported he had read an article that vaccines should be given four weeks apart and was concerned regarding having been vaccinated with ZOSTAVAX and flu vaccine (unspecified) in one injection. Additional information has been requested.
Covid Arm: 2" rash (width & length) around injection site.  Just noticed last night, 10 days after shot. Saw online that it's nothing to worry about, so will wait a week for it to go away. (Currently no headache, fever, pain. Only slight itching.)
Fever above 100, body aches, chills, muscle and joint pain, difficulty breathing.
Herpes Zoster; Information has been received from a lawyer regarding a case in litigation concerning a currently 73 years old female patient. The patient's medical history, concurrent conditions and concomitant medications were not provided.   The patient was prescribed the zoster vaccine live(ZOSTAVAX) vaccine by a healthcare provider for the long-term prevention of shingles and zoster-related conditions. On or about 03-JAN-2013, the patient was administered zoster vaccine live(ZOSTAVAX) (dose, route of administration, anatomical location, lot#, expiration date were unknown) by a pharmacist. On an unknown date, the patient was treated by a physician for the following injuries resulting from the patient's Zoster Vaccine Live (ZOSTAVAX) use: Herpes Zoster. The outcome of the event was unknown. Causality assessments were related.  Additional information has been requested.
Pain & swelling at injection site for about 3 hrs., applied ice pack; nausea & dizziness 2 hrs., overall itching 12 days off & on so far; coughing 12 days off & on so far; chest-tightness, wheezing, shortness of breath, accelerated heartbeat, itchy eyes, excessive urination, body aches, low fever, runny nose, swollen glands, sore throat & ears, hoarseness, lightheadedness, pain in armpit of injected arm, diarrhea, weakness for 12 days so far.
-Red swelling at inject site 10/5/20 spread to halfway down left arm -Somewhat "splotchy" down left arm on 10/7/20 - Fever of 101.6 10/5/20 evening. Down to 99.2 10/7/20. -Upset Stomach, fatigue -Overall felling of illness 10/5/20-10/7/20
Patient came with family member who was scheduled to get a COVID-19 injection. Patient was given a third Pfizer shot.
SUSPECTED CLINICAL VACCINATION FAILURE; SUSPECTED COVID-19 INFECTION; This spontaneous report received from a patient concerned a male of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (dose number in series was 1) (suspension for injection, route of admin not reported, batch number: 204A21A, expiry: UNKNOWN) dose was not reported, 1 total, administered on 11-MAY-2021 in left arm for prophylactic vaccination. No concomitant medications were reported.  On 28-DEC-2021, the patient experienced feeling tired, had headaches, fever, stuffy nose, chills, body aches, nasal congestion and cough (suspected covid-19 infection). On 30-DEC-2021, Laboratory data included: COVID-19 antigen test (NR: not provided) positive (suspected clinical vaccination failure). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the suspected clinical vaccination failure and suspected covid-19 infection was not reported. This report was serious (Other Medically Important Condition). This case is associated to regulatory authority.; Sender's Comments: V0- 20211266010-Covid-19 vaccine ad26.CoV-2.s- Suspected clinical vaccination failure. This event is considered not related. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event than the drug. Specifically: SPECIAL SITUATIONS
mom noted lt leg redness, swelling several hrs p/vax; APAP given; devel cold sx several days later, took pt to ER on 27FEB93 was told to apply warm compresses to lt leg by ER; MD dx lt leg abscess;
5 minutes after vaccine there was dizziness which passed after 10 minutes   30 minutes after vaccine there was headache, arm pain, muscle pain all over, fatigue, low grade fever, and sense of taste was altered. A constant metallic taste was in mouth and nothing (mints, brushing teeth, drinking water, etc.) removed it. Metallic taste resolved after 24 hours. Other symptoms lasted about 36 hours.
Pt to ED 9/12 for stroke eval, pt hypertension. 9/13 COVID+, rx remdesivir. 9/14 pt blood pressure is still elevated despite several blood pressure medication. 9/15 pt denies pain, no cp or sob. Pt discharged 9/15.
within the first 2-5 days patient experienced numbness and tingling in vaccinated arm (left). She also had a golf ball sized lump.  The numbness and tingling dissipated but on day 14 arm is still knotted at injection site and sore to the touch and movement. Patient is also experiencing abnormal menstrual periods. She has had two unexpected periods in these 14 days post injection. This is outside the timing of her normal cycle.
Patient received First vaccine dose of the Moderna COVID-19 on the 29 Sep 2021 and second dose on 12 Nov 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received First vaccine dose of the Moderna COVID-19 on the 29 Sep 2021 and second dose on 12 Nov 2021) in a 35-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 076C21A and 045C21A) for COVID-19 prophylaxis.     The patient had no allergies to medications, food and other products. The patient had no medical history related to mentioned adverse event and both acute and chronic illnesses at the time of vaccination. The patient had not received any other vaccine within 1 month prior to administration of Moderna COVID-19 vaccine. It was unknown whether the patient was ever tested positive or diagnosed with COVID-19 or not.    On 29-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received First vaccine dose of the Moderna COVID-19 on the 29 Sep 2021 and second dose on 12 Nov 2021). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received First vaccine dose of the Moderna COVID-19 on the 29 Sep 2021 and second dose on 12 Nov 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.   This case was linked to MOD-2022-615335 (Patient Link).
would get the second dose more than 35 days after the first; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (would get the second dose more than 35 days after the first) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (would get the second dose more than 35 days after the first). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (would get the second dose more than 35 days after the first) had resolved.
Child received rabies IgG on 1/18/19 in addition to his first rabies vaccination. He received a second rabies vaccination on 1/21/19. Third vaccination received 1/25/19. He seemed in his usual state of health until the afternoon of 1/27/18 when he felt warm. At a approximately 1600 hrs. the patient had a 45-90  second no-responsive episode, associated with eye deviation and loss of bladder control. No tonic-clonic activity; no post ictal  behavior. He received ibuprofen then and temp 45 minutes later was 102. No other illness symptoms then or when seen in the office 1/28/19. Exam then noted no mental status change and no focus of infection, other than a mild lacy rash on the extremities and trunk. No facial rash noted at any time. 1/29/19 - afebrile and at baseline.
Body aches. Joint pain. Fatigue. Diarrhea. Nausea. Injection site pain. Dizziness
No  adverse effect, patient was 16 at time of 1 & 2 dose Moderna Vaccine administration
Patient reports feeling tired and headaches. No lightheadedness, no hives or flushing. Patient was seen and assessed by EMS. BP 137/91, pulse 78, Spo2 100%, BS 152. Patient reports feeling better (symptoms improved) cleared by EMS
M.D. OFFICE ADMINISTERED PNEUMOVAX TO PATIENT IN NOVEMBER, 2019. PATIENT CAME IN TO PHARMACY ON 12/11/19 ASKING FOR PNEUMONIA SHOT. ON 12/17/19 PATIENT CALLED INTO PHARMACY AFTER REMEMBERING HE HAD ALREDY RECIEVED THE VACCINATION BY PHYSICIAN OFFICE TO FIND OUT IF HE WOULD BE OK BECAUSE HE RECEIVED SAME SHOT WITHING ONE MONTH PERIOD. I DISCUSSED WITH PATIENT. I ALSO CALLED PHARMACY CLINICAL TO DICUSS. LAST, I CALLED DR.'S OFFICE TO LET THEM KNOW. ALL AGREE NO ADVERSE REACTION.
Patient tested positive following full COVID-19 vaccination.; Patient tested positive following full COVID-19 vaccination.; This is a spontaneous report from a non-contactable other health care professional. A 43-year-old male patient received bnt162b2 (BNT162B2, Formulation: Solution for injection, Batch/Lot Number: EN5318) dose 2 via an unspecified route of administration 24Feb2021 (at the age of 42-years-old) as dose 2, single and bnt162b2 (BNT162B2, Formulation: Solution for injection, Batch/Lot Number: EN5318) dose 1 via an unspecified route of administration 05Feb2021 (at the age of 42-years-old) as dose 1, single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient tested positive following full COVID-19 vaccination on 20Aug2021. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination, the patient has been tested for COVID-19. The patient underwent lab tests and procedures which included Covid Test was positive on 20Aug2021. The outcome of the event was unknown.  No follow-up attempts are possible. No further information is expected. ; Sender's Comments: Based on known drug safety profile, there is reasonable possibility of causal association between the events drug ineffective and covid-19 and BNT162B2.
Patient states that he had to go to the hospital the same night as the immunization with flu-like symptoms (nausea, tired, etc.). Hospital kept patient and claims treated him for influenza.
Information has been received from a medical assistant concerning multiple unspecified patients of unknown age and gender. The patients' concurrent conditions, medical histories and concomitant therapies were not provided. On unknown dates, the patients were vaccinated with doses of improperly stored ROTATEQ (lot # L026741, expiration date 18-MAY-2017; dose and route were unknown). The vaccines were exposed to temperature excursion of 1 degree centigrade for 12 hours and 1 degree centigrade for 10 hours. There were no previous temperature excursions. Data logger was involved. No adverse effects were reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
Six hours after administration patient was feverish (temp over 101), nausea, vomiting, exhausted and chills that lasted for 2 days.  Then last Friday February 26, 2021 exact same symptoms recurred that lasted 2 days as well.  Called doctor both times to get nausea medication.  Doctor prescribed 25 mg of Promethazine.
Post vax, developed sterile abscess 1 month later that took about 6 weeks to resolve, after drainage and antibiotics at 7 months re-vax and again developed sterile abscess.